Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer

This study is testing whether a class of diabetes medication called SGLT2 inhibitors (specifically dapagliflozin) taken before prostate surgery can slow cancer growth in men with localized high-risk prostate cancer. Researchers are looking at changes in the prostate tumor before and after the drug is taken. **You may be eligible if...** - You are 18 or older with confirmed prostate cancer classified as unfavorable intermediate, high-risk, or very high-risk - You are planning to have your prostate surgically removed (radical prostatectomy) as your primary treatment - You have a measurable tumor on prostate MRI - You have adequate blood counts and organ function - Your blood sugar is reasonably controlled (if you have type 2 diabetes) **You may NOT be eligible if...** - You have previously used SGLT2 inhibitors or thiazolidinedione diabetes drugs - You have type 1 or insulin-dependent diabetes - You have had a stroke or TIA in the last 5 years - You have severe kidney disease (low kidney filtration rate) - You have frequent urinary tract or yeast infections - You have had another cancer in the past 2 years (with exceptions) - You have pelvic metal implants that would interfere with MRI Talk to your doctor to see if this trial is right for you.